Biotechnology stocks and sector-related exchange traded funds have been gaining momentum as investors return to this downtrodden segment of the market.
Over the past month, the Virtus LifeSci Biotech Clinical Trials ETF (BBC) gained 15.5%, the Virtus LifeSci Biotech Products ETF (BBP) rose 12.8%, the SPDR S&P Biotech ETF (XBI) increased 11.3% and the ALPS Medical Breakthroughs ETF (SBIO) was up 10.9%.
A Nasdaq benchmark for biotechnology stocks has plunged almost a third from its all-time high last August after optimism over developments to counter the COVID-19 pandemic bolstered the industry and led to concerns over elevated valuations.
However, some hedge fund managers now argue that prices have pulled back too far relative to these companies’ drug development outlook and their remaining cash levels. Consequently, more investors have started picking up stocks on the cheap.
“This is the worst correction [in the biotech sector] I have seen in my 22-year career,” Michele Gesualdi, founder of London-based investment group Infinity Investment Partners, told the Financial Times. “We have never seen stress like this.”
Gesualdi believed that the sector is, on all metrics, “as cheap as it has ever been.”
The high-growth biotech segment has also fallen victim to the broader sell-off in growth names, following the rising interest rate outlook.
“Coming out of the COVID tunnel, seeing inflation rise at [a] higher pace than predicted by any central bank, the [biotech] sector has faced unexpected adversity,” Philippe Wolgen, chief executive of Australian biotech Clinuvel Pharmaceuticals, told the Financial Times.
After a “catastrophic” plunge, fund managers and bankers “are openly expressing their aversion to perpetuating these risky ventures,” Wolgen added, referring to backing companies with little prospect of revenues over the near term. However, he argued that investors were starting to look at “genuine business[es]” in the sector.
Fueling the rally in the biotech sector, hedge funds are on the lookout for bargain picks among the oversold biotech market, the Financial Times reported.
For more news, information, and strategy, visit VettaFi.
vettafi.com is owned by VettaFi, which also owns the index provider for SBIO. VettaFi is not the sponsor of SBIO, but VettaFi’s affiliate receives an index licensing fee from the ETF sponsor.
